Miao-Miao Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miao-Miao Tian has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Hao Zhu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
3 shared publications - Jian-Qiang Yu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
3 shared publications - Shan Liu
Key Laboratory of Protection, Development, and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Department of Pharmacology, Peptide & Protein Drug Research Center, College of Pharmacy, School of Pharmacy, Ningxia Medical University, Yinchuan, China
3 shared publications - Jia-Mei Yang
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications - Juan Du
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications - Lin Ma
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications
Latest Publications
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 468
Study on the Analgesic Mechanism of Aloperine in Mice with Neuropathic Pain Based on the p38MAPK/FKN/CX3CR1 Pathway
A lesion or disease of the somatosensory nervous system causes neuropathic pain (NP). Previous experiments have demonstrated that aloperine (ALO) exhibits antiallodynic effects on neuropathic pain in mice; however, the mechanism underlying its analgesic action remains unclear. This study investigated the analgesic mechanism of ALO on neuropathic pain in mice using a chronic constriction injury (CCI) model. Experiments were conducted using the ALO and p38MAPK inhibitor SB 203580. In vivo experiments demonstrated that ALO played an analgesic role by inhibiting p38MAPK phosphorylation, and it improved mechanical allodynia, cold allodynia, and hot hyperalgesia in CCI mice, as well as having a protective effect on injured sciatic nerves. The combined administration of a subthreshold dose of ALO (20 mg/kg) with the p38MAPK inhibitor SB203580 (20 mg/kg) produced significant analgesic effects, suggesting that ALO likely shares a common target with SB203580, namely p38MAPK. Fluorescence double staining indicated that the antiallodynic effect of ALO may be related to its inhibition of the p38MAPK/FKN/CX3CR1 pathway in the spinal cord, and it may play a role in regulating the expression of p38MAPK in microglial cells. In vitro studies have shown that ALO can reduce the activation of BV2 cells, inhibit p38MAPK phosphorylation in microglia, and play a role in regulating the p38MAPK protein. In conclusion, our results suggest that the analgesic mechanism of aloperine is associated with its inhibition of the FKN/CX3CR1 pathway, which is regulated by p38MAPK phosphorylation in spinal microglia. This study provides new potential targets for the analgesic mechanism of aloperine. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 468
Study on the Analgesic Mechanism of Aloperine in Mice with Neuropathic Pain Based on the p38MAPK/FKN/CX3CR1 Pathway
A lesion or disease of the somatosensory nervous system causes neuropathic pain (NP). Previous experiments have demonstrated that aloperine (ALO) exhibits antiallodynic effects on neuropathic pain in mice; however, the mechanism underlying its analgesic action remains unclear. This study investigated the analgesic mechanism of ALO on neuropathic pain in mice using a chronic constriction injury (CCI) model. Experiments were conducted using the ALO and p38MAPK inhibitor SB 203580. In vivo experiments demonstrated that ALO played an analgesic role by inhibiting p38MAPK phosphorylation, and it improved mechanical allodynia, cold allodynia, and hot hyperalgesia in CCI mice, as well as having a protective effect on injured sciatic nerves. The combined administration of a subthreshold dose of ALO (20 mg/kg) with the p38MAPK inhibitor SB203580 (20 mg/kg) produced significant analgesic effects, suggesting that ALO likely shares a common target with SB203580, namely p38MAPK. Fluorescence double staining indicated that the antiallodynic effect of ALO may be related to its inhibition of the p38MAPK/FKN/CX3CR1 pathway in the spinal cord, and it may play a role in regulating the expression of p38MAPK in microglial cells. In vitro studies have shown that ALO can reduce the activation of BV2 cells, inhibit p38MAPK phosphorylation in microglia, and play a role in regulating the p38MAPK protein. In conclusion, our results suggest that the analgesic mechanism of aloperine is associated with its inhibition of the FKN/CX3CR1 pathway, which is regulated by p38MAPK phosphorylation in spinal microglia. This study provides new potential targets for the analgesic mechanism of aloperine. Graphical Abstract
- 11 March 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 947, 175646
Targeting the chemokine ligand 2–chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
- 11 March 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 947, 175646
Targeting the chemokine ligand 2–chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
- Open Access
Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components
Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety. This disease imposes a significant burden on both the somatic and mental health of patients; indeed, some patients have referred to neuropathic pain as being ‘worse than death’. The pharmacological agents that are used to treat neuropathic pain at present can produce mild effects in certain patients, and induce many adverse reactions, such as sedation, dizziness, vomiting, and peripheral oedema. Therefore, there is an urgent need to discover novel drugs that are safer and more effective. Natural compounds from medical plants have become potential sources of analgesics, and evidence has shown that glycosides alleviated neuropathic pain via regulating oxidative stress, transcriptional regulation, ion channels, membrane receptors and so on. In this review, we summarize the epidemiology of neuropathic pain and the existing therapeutic drugs used for disease prevention and treatment. We also demonstrate how glycosides exhibit an antinociceptive effect on neuropathic pain in laboratory research and describe the antinociceptive mechanisms involved to facilitate the discovery of new drugs to improve the quality of life of patients experiencing neuropathic pain.
Open AccessGlycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components
Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety. This disease imposes a significant burden on both the somatic and mental health of patients; indeed, some patients have referred to neuropathic pain as being ‘worse than death’. The pharmacological agents that are used to treat neuropathic pain at present can produce mild effects in certain patients, and induce many adverse reactions, such as sedation, dizziness, vomiting, and peripheral oedema. Therefore, there is an urgent need to discover novel drugs that are safer and more effective. Natural compounds from medical plants have become potential sources of analgesics, and evidence has shown that glycosides alleviated neuropathic pain via regulating oxidative stress, transcriptional regulation, ion channels, membrane receptors and so on. In this review, we summarize the epidemiology of neuropathic pain and the existing therapeutic drugs used for disease prevention and treatment. We also demonstrate how glycosides exhibit an antinociceptive effect on neuropathic pain in laboratory research and describe the antinociceptive mechanisms involved to facilitate the discovery of new drugs to improve the quality of life of patients experiencing neuropathic pain.